6 days Ago By ABMN Staff
Wellington Management Group LLP cut its stake in Novavax, Inc. ( NASDAQ:NVAX – Free Report ) by 11.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission.
The institutional investor owned 64,538 shares of the biopharmaceutical company’s stock after selling 8,577 shares during the period. Wellington Management Group LLP’s holdings in Novavax were worth $519,000 as of its most recent filing with the Securities & Exchange Commission. Other institutional investors and hedge funds have also made changes to their positions in the company.
Spire Wealth Management purchased a new stake in shares of Novavax in the 4th quarter valued at $29,000. New Age Alpha Advisors LLC purchased a new position in shares of Novavax during the 4th quarter valued at approximately $35,000. KBC Group NV lifted its holdings in Novavax by 97.
0% during the fourth quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 3,917 shares in the last quarter. TigerOak Management L.
L.C. acquired a new stake in Novavax in the 4th quarter worth about $86,000.
Finally, AlphaQuest LLC boosted its stake in shares of Novavax by 290.1% in the fourth quarter. AlphaQuest LLC now owns 10,677 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 7,940 shares during the last quarter.
53.04% of the stock is currently owned by institutional investors and hedge funds. Novavax Trading Up 9.
4 % Shares of NASDAQ NVAX opened at $6.41 on Tuesday. The business’s fifty day simple moving average is $7.
43 and its 200-day simple moving average is $8.75. Novavax, Inc.
has a 12-month low of $3.81 and a 12-month high of $23.86.
The stock has a market cap of $1.03 billion, a P/E ratio of -2.84, a PEG ratio of 2.
85 and a beta of 3.15. Wall Street Analysts Forecast Growth A number of research firms have commented on NVAX.
TD Cowen upgraded shares of Novavax to a “hold” rating in a report on Thursday, February 27th. BTIG Research assumed coverage on shares of Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.
00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.
com, the stock has a consensus rating of “Hold” and a consensus target price of $18.00. Read Our Latest Stock Analysis on NVAX About Novavax ( Free Report ) Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.
It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. Featured Stories Want to see what other hedge funds are holding NVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novavax, Inc.
( NASDAQ:NVAX – Free Report ). Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter .
.
